Watch ABBV. Know when insiders buy.
One email the day a filing lands. Free.
ABBV
AbbVie Inc.
284.80
−4.28 −1.48%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
34
FLAG · shorts 34
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 1
buys / sells · latest disclosed Sep 18
Big money
3 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $503.3BP/E 80.5DIV YIELD 2.40%FCF YIELD 3.62%REV TTM $64.4B +10.4%NET INCOME $6.3B +67.7%NET DEBT $57.9B52W 197.38 – 289.08SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $17B | +10.2% | 74.7% | $6.4B | $3.6B | +285.2% | 2.03 | $3.4B | $322M | $3.1B | Aug 3 |
| Q1 2026 · Mar 31 | $15B | +12.4% | 71.9% | $4B | $695M | −46.0% | 0.39 | $3.8B | $265M | $3.6B | Aug 3 |
| Q4 2025 · Dec 31 | $16.6B | +10.0% | 72.6% | $4.5B | $1.8B | — | 1.02 | $5.2B | $329M | $4.9B | Aug 3 |
| Q3 2025 · Sep 30 | $15.8B | +9.1% | 66.4% | $1.9B | $186M | −88.1% | 0.10 | $7B | $381M | $6.6B | Aug 3 |
| Q2 2025 · Jun 30 | $15.4B | +6.6% | 71.8% | $4.9B | $938M | −31.5% | 0.52 | $5.2B | $269M | $4.9B | Aug 3 |
| Q1 2025 · Mar 31 | $13.3B | +8.4% | 70.0% | $3.7B | $1.3B | −6.1% | 0.72 | $1.6B | $235M | $1.4B | Aug 3 |
| Q4 2024 · Dec 31 | $15.1B | +5.6% | 70.9% | −$1.5B | −$22M | −102.7% | -0.02 | $7B | $291M | $6.8B | Feb 20 |
| Q3 2024 · Sep 30 | $14.5B | +3.8% | 70.9% | $3.8B | $1.6B | −12.2% | 0.88 | $5.4B | $249M | $5.2B | Feb 20 |
| Q2 2024 · Jun 30 | $14.5B | — | 70.9% | $4B | $1.4B | — | 0.77 | $2.3B | $241M | $2B | Feb 20 |
| Q1 2024 · Mar 31 | $12.3B | — | 66.7% | $2.8B | $1.4B | — | 0.77 | $4B | $193M | $3.8B | Feb 20 |
| Q4 2023 · Dec 31 | $14.3B | — | 60.1% | $3.2B | $822M | — | 0.46 | $4.8B | $205M | $4.5B | Feb 20 |
| Q3 2023 · Sep 30 | $13.9B | — | 53.4% | $2.3B | $1.8B | — | 1.00 | $7.6B | $219M | $7.4B | Feb 20 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $61.2B | 70.2% | $15.1B | $4.2B | 6.9% | 2.36 | $19B | $1.2B | $17.8B | $980M | $11.7B |
| FY2024 · to Dec 31 | $56.3B | 70.0% | $9.1B | $4.3B | 7.6% | 2.39 | $18.8B | $974M | $17.8B | $1.7B | $11B |
| FY2023 · to Dec 31 | $54.3B | 62.4% | $12.8B | $4.9B | 9.0% | 2.72 | $22.8B | $777M | $22.1B | $2B | $10.5B |
| FY2022 · to Dec 31 | $58.1B | 70.0% | $18.1B | $11.8B | 20.4% | 6.63 | $24.9B | $695M | $24.2B | $1.5B | $10B |
| FY2021 · to Dec 31 | $56.2B | 69.0% | $17.9B | $11.5B | 20.5% | 6.45 | $22.8B | $787M | $22B | $934M | $9.3B |
| FY2020 · to Dec 31 | $45.8B | 66.4% | $11.4B | $4.6B | 10.1% | 2.72 | $17.6B | $798M | $16.8B | $978M | $7.7B |
Every number comes from AbbVie Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.